Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion
- 1 September 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 76 (6) , 903-908
- https://doi.org/10.1097/01.tp.0000089006.00653.64
Abstract
MO2ART (monitoring of 2-hr absorption in renal transplantation) is the first prospective, multicenter trial of cyclosporine (CsA) blood level 2 hr postdose (C2) monitoring in de novo kidney recipients receiving CsA microemulsion (ME) (Neoral; Novartis, Basel, Switzerland). Efficacy and safety results from the first 3 months are presented here. MO2ART is a 12-month, open-label, randomized study involving 296 patients. In all patients, the dose of CsA-ME was adjusted to achieve protocol-defined C2 targets of 1.6 to 2.0 microg/mL for the first month, with subsequent tapering. Randomization into two target groups occurred at 3 months. All patients received steroids and mycophenolate mofetil (89%) or azathioprine. For patients with delayed graft function, the protocol permitted reduced C2 targets and prophylactic administration of antibodies. At 3 months, overall incidence of biopsy-proven acute rejection was 11.5%. Median serum creatinine was 132 micromol/L. Patient and graft survival were 96.6% and 91.2%, respectively. C2 levels greater than 1.6 microg/mL were achieved within 5 days by 60.6% of patients with immediate graft function and 19.5% of patients with delayed graft function. Prophylactic antibodies were used in 15% of the total population. Twenty-four patients (8.1%) experienced serious adverse events with a suspected relation to CsA, and 26 patients (8.8%) discontinued the study because of adverse events (n=15) or after a switch in immunosuppression after rejection episodes (n=11). Patient management by C2 monitoring resulted in a low incidence of biopsy-proven acute rejection in standard risk de novo kidney recipients, 85% of whom did not receive prophylactic antibodies. CsA-ME with C2 monitoring provides excellent short-term efficacy and safety among de novo renal transplant patients.Keywords
This publication has 16 references indexed in Scilit:
- Cyclosporine Microemulsion (Neoral®) Absorption Profiling and Sparse-sample Predictors During the First 3 Months after Renal TransplantationAmerican Journal of Transplantation, 2002
- Randomized, International Study of Cyclosporine Microemulsion Absorption Profiling in Renal Transplantation with Basiliximab ImmunoprophylaxisAmerican Journal of Transplantation, 2002
- Neoral C2 monitoring in pediatric liver transplant recipientsTransplantation Proceedings, 2001
- Approaching the Therapeutic Window for Cyclosporine in Kidney TransplantationJournal of the American Society of Nephrology, 2001
- COMPARISON OF MICROEMULSION AND CONVENTIONAL FORMULATIONS OF CYCLOSPORINE A IN PREVENTING ACUTE REJECTION IN DE NOVO KIDNEY TRANSPLANT PATIENTS1Transplantation, 1999
- Sandimmune®to neoral®conversion and value of abbreviated AUC monitoring in stable pediatric kidney transplant recipientsPediatric Transplantation, 1999
- NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVETransplantation, 1999
- PEAK CYCLOSPORINE LEVELS (Cmax) CORRELATE WITH FREEDOM FROM LIVER GRAFT REJECTIONTransplantation, 1999
- RANDOMIZED TRIAL OF CYCLOSPORINE MICROEMULSION (NEORAL) VERSUS CONVENTIONAL CYCLOSPORINE IN LIVER TRANSPLANTATIONTransplantation, 1998
- REDUCED INTER- AND INTRASUBJECT VARIABILITY IN CYCLOSPORINE PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS TREATED WITH A MICROEMULSION FORMULATION IN CONJUNCTION WITH FASTING, LOW-FAT MEALS, OR HIGH-FAT MEALS1,2Transplantation, 1995